نام كاربري
كلمه ورود
درخواست عضویت
کلمه ورود را فراموش کرده ام

صاحب امتیاز:جامعه جراحان ایران
مدیر مسئول:دکتر ایرج فاضل
سردبیر: دکتر سید عباس میرمالک
مدیر اجرایی:

آدرس:تهران، میدان هروی، خیابان وفامنش، کوچه جمالی غربی (گیتی)، پلاک 65-
کد پستی:1668753963
تلفن:26755411
دورنگار:26912113
پست الکترونیک:info@ijs.ir

صفحه نخست :: بخش مدیریت نشریهصفحه قبل

Journal Title: بهار 86
Article title: The Effective Chemotherapy Regimen for Advanced Unresectable Gastric Cancer

Article PDF File:
Page From: 81 To: 87      

Article abstract:
Introduction & Objective: In a prospective multicentric phase II trial, we evaluated the efficacy and toxicity of combination of docetaxel, cisplatin and 5fu/lv (DCF) in a group of untreated patients with unresectable advanced and metastatic Gastric Cancer. Materials & Methods: Fifty six patients with locally advanced and metastatic Gastric cancer were enrolled in this study. Docetaxel, 75mg/m2 in day 1, Cisplatin 75mg/m2 in day 1, 5-fu 750mg/m2/ for day 1 –3 with continuous infusion with folinic acid support were administered. The above regimen were given every 3 weeks for total of 6 cycles. The primary end points were time to progression (TTP) and overall survival (OS). Results: In 56 assigned patients (Male = 36, Female = 20) with median age of 56 year, 40% had already undergone unsuccessful laparatomy, a total of 274 cycles of above regimen were given. The average of received cycles were 5 cycles. In a 16 months of follow up 75% of patients showed progression, in evaluation after 19 months 65% of patients died and overall survival was 10 months. Until this report 19 out of 56 (35%) were alive for more than a year. Time to progression with DCF was almost two times compared to prior chemotherapy regimen. The most important toxicity of this regimen were neutropenic fever in 12% of patients, gastrointestinal toxicity and neuropathy. Conclusions: Adding Docetaxel to CF significantly improved RR, TTP, and OS. The above results have associated with brief increase in toxicity, the overall quality of life was better, therefore, DCF regimen could be one of the standard options for patients with untreated advanced gastric cancers.

Article KeyWords:
Advanced Gastric Cancer, Chemotherapy, Docetaxel

Article Authors:
دكتر حميد عطاريانFirst AuthorHattarian@Hotmail.com
دكتر مجتبي قديانيOther Author
دكتر حميد رضوانيOther Author
دكتر ابوالقاسم اباسهلOther Author




بالای صفحه
صفحه اصلی  |  تماس با ما  |  آرشیو مجله  |  نقشه سایت  |  عضویت  |  ارسال مقاله  |  پیگیری مقاله

استفاده از مطالب این سایت با ذکر نام سایت مجاز می باشد   -   Copyright © 2007, 2009 - Last Update 5-11-2009
Powered By www.itpco.net    www.itpco.ir
( ITPCO ) شرکت توسعه انفورماتیک ایران
تولید کننده سیستم های تخصصی مدیریت نشریات و همایش ها و مورد تائید کمیسیون نظارت بر نشریات پزشکی وزارت بهداشت درمان و آموزش پزشکی کشور